Evaluation of Polysaccharide Typhim Vi Antibody Response as a predictor of Humoral Immunodeficiency in Haematological Malignancies

Evaluation of Polysaccharide Typhim Vi Antibody Response as a predictor of Humoral Immunodeficiency in Haematological Malignancies

Copyright © 2019 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 210(2020) vom: 20. Jan., Seite 108307
1. Verfasser: Ochoa-Grullón, J (VerfasserIn)
Weitere Verfasser: Benavente Cuesta, C, Pérez López, C, Peña Cortijo, A, Rodríguez de la Peña, A, Álvarez Carmona, A, Mateo Morales, M, Llano-Hernández, K, Williams, L J, Rodríguez de Frías, E, Guevara-Hoyer, K, Cordero Torres, G, Orte, C, Fernández-Arquero, M, Fernández-Paredes, L, Serrano-García, I, Recio, M J, Pérez de Diego, R, Martínez, R, Sánchez-Ramón, S
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2020
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Observational Study Haematological malignancies Hypogammaglobulinemia Pneumo23 Specific polysaccharide ab response Typhim vi Antibodies, Bacterial Polysaccharides, Bacterial Typhoid-Paratyphoid Vaccines Vi polysaccharide vaccine, typhoid
LEADER 01000naa a22002652 4500
001 NLM303626283
003 DE-627
005 20231225113229.0
007 cr uuu---uuuuu
008 231225s2020 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2019.108307  |2 doi 
028 5 2 |a pubmed24n1012.xml 
035 |a (DE-627)NLM303626283 
035 |a (NLM)31760095 
035 |a (PII)S1521-6616(19)30261-X 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Ochoa-Grullón, J  |e verfasserin  |4 aut 
245 1 0 |a Evaluation of Polysaccharide Typhim Vi Antibody Response as a predictor of Humoral Immunodeficiency in Haematological Malignancies 
264 1 |c 2020 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 31.07.2020 
500 |a Date Revised 31.07.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2019 Elsevier Inc. All rights reserved. 
520 |a An increasing healthcare challenge in the management of haematological malignancy (HM) is secondary immunodeficiency. From January 2019, the EMA included the evaluation of specific antibody (Ab) responses to better select patients for immunoglobulin replacement therapy (IgRT). We evaluated Ab responses to pneumococcal and Salmonella typhi pure polysaccharide immunization in a cohort of 42 HM patients and 24 healthy-controls. Pre-post specific Ab concentrations were measured by ELISA at 4 weeks. Globally, significantly lower Typhim Vi (TV) seroprevalence (9%) compared to 23-valent pneumococcal polysaccharide vaccine (PPV) (76%) (p <0.001) was observed. TV non responders (88%) were higher than PPV non responders (62%) (p <0.0001) and correlated better to infectious history. By ROC analysis, pre-post 5-fold TV increase was the best cut-off to discriminate HM with recurrent infections and controls (sensitivity 91%, specificity 100%). Despite the small sample cohort, our results suggest that specific anti-S typhi Ab response is a useful complementary assay in the diagnosis and management decision of SID to HM 
650 4 |a Journal Article 
650 4 |a Observational Study 
650 4 |a Haematological malignancies 
650 4 |a Hypogammaglobulinemia 
650 4 |a Pneumo23 
650 4 |a Specific polysaccharide ab response 
650 4 |a Typhim vi 
650 7 |a Antibodies, Bacterial  |2 NLM 
650 7 |a Polysaccharides, Bacterial  |2 NLM 
650 7 |a Typhoid-Paratyphoid Vaccines  |2 NLM 
650 7 |a Vi polysaccharide vaccine, typhoid  |2 NLM 
700 1 |a Benavente Cuesta, C  |e verfasserin  |4 aut 
700 1 |a Pérez López, C  |e verfasserin  |4 aut 
700 1 |a Peña Cortijo, A  |e verfasserin  |4 aut 
700 1 |a Rodríguez de la Peña, A  |e verfasserin  |4 aut 
700 1 |a Álvarez Carmona, A  |e verfasserin  |4 aut 
700 1 |a Mateo Morales, M  |e verfasserin  |4 aut 
700 1 |a Llano-Hernández, K  |e verfasserin  |4 aut 
700 1 |a Williams, L J  |e verfasserin  |4 aut 
700 1 |a Rodríguez de Frías, E  |e verfasserin  |4 aut 
700 1 |a Guevara-Hoyer, K  |e verfasserin  |4 aut 
700 1 |a Cordero Torres, G  |e verfasserin  |4 aut 
700 1 |a Orte, C  |e verfasserin  |4 aut 
700 1 |a Fernández-Arquero, M  |e verfasserin  |4 aut 
700 1 |a Fernández-Paredes, L  |e verfasserin  |4 aut 
700 1 |a Serrano-García, I  |e verfasserin  |4 aut 
700 1 |a Recio, M J  |e verfasserin  |4 aut 
700 1 |a Pérez de Diego, R  |e verfasserin  |4 aut 
700 1 |a Martínez, R  |e verfasserin  |4 aut 
700 1 |a Sánchez-Ramón, S  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 210(2020) vom: 20. Jan., Seite 108307  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:210  |g year:2020  |g day:20  |g month:01  |g pages:108307 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2019.108307  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 210  |j 2020  |b 20  |c 01  |h 108307